Hasan, Md Kamrul
Ghia, Emanuela M. http://orcid.org/0000-0002-6060-6106
Rassenti, Laura Z.
Widhopf, George F. II
Kipps, Thomas J. http://orcid.org/0000-0002-0064-4549
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01-CA236361)
California Institute for Regenerative Medicine (DR3-06924)
Article History
Received: 17 February 2020
Revised: 11 August 2020
Accepted: 5 October 2020
First Online: 23 October 2020
Compliance with ethical standards
:
: Cirmtuzumab was developed by TJK and licensed from the University of California, San Diego, to Oncternal Therapeutics, Inc., which provided stock/options and funding to the University of California, San Diego, and to TJK.